Targeted EpiEditing Regel Therapeutics focuses on a Targeted EpiEditing platform to address severe genetic diseases, presenting a potential opportunity to license or co-develop genome editing technologies, collaborate on research programs, or provide contract research and testing services to accelerate client programs.

Leadership Change Recent appointment of Stephen J. Farr as CEO signals strategic direction and potential for new partnerships, funding rounds, or business development initiatives; partner with the new leadership to align on collaboration frameworks, joint ventures, or investor-led introductions.

Moderate Scale With 11-50 employees and early-stage funding, Regel offers a lean partner for agile collaborations, enabling quick pilot programs, shared risk research agreements, and targeted exploratory projects with larger biotech firms seeking innovation in epigenetic editing.

Revenue Potential Current revenue range ($10M–$25M) and modest funding (~$1M) indicate opportunities for milestone-driven partnerships, co-development deals, or contract research arrangements to scale therapeutic programs and attract further investment.

Massachusetts Focus Based in Cambridge, MA, Regel sits in a dense biotech ecosystem with proximity to academic and corporate collaborators; target nearby pharma and CRO/CMO partners for joint discovery programs, access to talent, and streamlined regulatory advisory pathways.